BIDMC is collaborating with Deerfield, a healthcare investment firm committed to accelerating discovery of novel therapeutics within BIDMC faculty laboratories into clinical therapeutics. Brookline Avenue Innovations (BAI) is a Deerfield company that will support BIDMC’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. BAI will fund projects with the aim of discovering novel therapeutics to improve the lives of patients. Through BAI, Deerfield has committed up to $130 million over the next ten years to support promising translational research from BIDMC. This collaboration will provide operational support and may make additional capital investments into spin-off companies that emerge from BAI projects that show commercial potential. 

Principal Investigators whose principal employer is BIDMC or who have a faculty appointment at BIDMC and are therefore subject to BIDMC’s institutional policies are eligible to apply.

Please contact Cindy Wong at TVO (cwong2@bidmc.harvard.edu) for more information on proposal submission to BAI.

No – We welcome applications from all therapeutic areas.

Eligible projects must be free from any Intellectual Property (IP) obligations to other industry partners that may restrict the licensing and practice of the IP (by virtue of industry sponsored research agreements, material transfer agreements, or other contractual or intellectual property entanglements). If you have any questions about whether or not such obligations exist with your project, you should consult with your Technology Licensing Team at TVO.